Today's Rundown UnitedHealth to offer $1.5B in financial support to members, including premium credits Takeda, CSL-led alliance and NIH to test COVID-19 plasma treatment this summer GSK taps experimental arthritis antibody to calm the cytokine storm hitting COVID-19 patients Moderna eyes 'early summer' start for phase 3 COVID-19 vaccine trial Pfizer tags 3 U.S. manufacturing sites for possible COVID-19 vaccine launch Healthcare roundup: Oscar, Uno partner on MA financial assistance; HHS awards more than $580M to expand testing Biopharma roundup: Endo withdraws 2020 guidance; Sarepta's Vyondys launch slows GBT chief blames COVID-19 for 'clear' slowdown in Oxbryta launch, but analysts are still impressed Portraits in Healthcare: Intermountain ICU doctor calls COVID-19 'a lonely disease' Sherlock's quick, CRISPR-based coronavirus test gets emergency nod Dignity Health and Cleveland Clinic among biggest winners of initial round of COVID-19 funding Bristol Myers Squibb's blood thinner Eliquis soars on COVID-19 demand, but Opdivo could suffer: execs Teva generics benefit from COVID-19 bump––but the boom may not last Livongo raises 2020 revenue guidance as use of remote monitoring accelerates PPD latest pandemic victim as it too yanks full-year guidance Featured Story | | | Thursday, May 7, 2020 UnitedHealth Group will make more than $1.5 billion in financial assistance available to its members. |
|
|---|
|
Top Stories Thursday, May 7, 2020 Takeda and its plasma-focused peers are wasting no time. One month after joining forces to create an unbranded plasma-based treatment for COVID-19, the partners, along with the NIH, are gearing up for a global clinical trial set to kick off this summer. The study will lay the groundwork for a regulatory submission for the medicine. Thursday, May 7, 2020 GlaxoSmithKline is hard at work with partner Sanofi in getting a vaccine tested for COVID-19, but this morning it said it was now also entering the race to treat patients already hit with the disease. Thursday, May 7, 2020 Moderna is finalizing the protocol for a phase 3 trial of its COVID-19 vaccine with a view to starting the study early in the summer. The establishment of the timeline, which follows FDA clearance to run a phase 2 trial, puts Moderna on track to win approval for its mRNA vaccine mRNA-1273 next year. Thursday, May 7, 2020 Global coronavirus vaccine makers have been rolling out details about their manufacturing and launch plans—even ahead of any clinical data. Now, Pfizer says it will draw on three sites in the U.S., plus one in Belgium, for the early stages of a launch, provided its BioNTech-partnered shot wins a green light. Thursday, May 7, 2020 FierceHealthcare's ongoing coverage of how the coronavirus is impacting the healthcare industry. Thursday, May 7, 2020 Endo International withdrew its 2020 guidance due to the pandemic and provided other updates about expected effects. Sarepta had a launch hit by the pandemic, while Alnylam lowered its guidance. Thursday, May 7, 2020 Global Blood Therapeutics' sickle cell disease medicine Oxbryta got off to a hot start after a November FDA approval. But early in its launch, execs now say they're seeing a "clear headwind" from the COVID-19 pandemic. Lately, new patient starts have tanked by 60%, CEO Ted Love said. Thursday, May 7, 2020 Dixie Harris, M.D., shares her experiences during a two-week stretch in the ICU of Southside Hospital in New York as the hospital faced a crush of COVID-19 cases. Thursday, May 7, 2020 The FDA granted its first emergency authorization for a CRISPR-based test for COVID-19, developed by Sherlock Biosciences, designed to turn results around in about an hour compared to the four to six hours needed for other molecular diagnostics. Thursday, May 7, 2020 Dignity Health and Cleveland Clinic were among the hospitals that got the most money from the initial round of COVID-19 funding allocations. Thursday, May 7, 2020 Bristol Myers Squibb CEO Giovanni Caforio credited COVID-19-related stocking for high sales of some products in the first quarter, including Eliquis, a blood thinner that's being snapped up to reduce clotting risk in patients with the virus. But the pandemic has limited access to oncology clinics and other non-COVID-19 services, raising challenges that could impact sales later this year. Thursday, May 7, 2020 With its multibillion-dollar restructuring plan in the rearview mirror, Teva is pinning its future growth on two of its branded meds with high hopes. But generics are still central to the Israeli drugmaker's business, and increased demand due to COVID-19 gave Teva a welcome gift in the first three months of the year. Thursday, May 7, 2020 The COVID-19 pandemic has accelerated the use of virtual care, and companies like Livongo stand to benefit financially. Livongo, a chronic disease management company that has a strong focus on diabetes, reported a 115% jump in first-quarter revenue, increasing from $32 million a year ago to $68.8 million. Thursday, May 7, 2020 The ongoing COVID-19 uncertainty and the impact on its trials has caused PPD to pull its 2020 guidance, like so many other CROs, to try to work its way through the coming financial year. |
